IN THE CLAIMS:

Please enter the attached listing of claims into the application. This listing of claims replaces all prior listing of claims in the application.

LISTING OF CLAIMS

1. (Previously Presented) An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:5.

2. (Previously Presented) An isolated polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO:5.

3. (Currently Amended) The isolated polypeptide of claim 1 or 2, wherein the cysteine residues are intramolecularly cross-linked via a disulfide bond.

4. (Cancelled)

5. (Currently Amended) The isolated polypeptide of claim[[s]] 1, further comprising from 1 to 15 additional amino acid at the N- or C-terminus of the polypeptide comprising SEQ ID NO:5.

6. (Currently Amended) The isolated polypeptide of claim[[s]] 1, further comprising from 1 to 10 additional amino acid at the N- or C-terminus of the polypeptide comprising SEQ ID NO:5.

7. (Currently Amended) The isolated polypeptide of claim[[s]] 1, further comprising from 1 to 5 additional amino acid at the N- or C-terminus of the polypeptide comprising SEQ ID NO:5.

8. (Currently Amended) The isolated polypeptide of claim[[s]] 1, further comprising from 1 to 3 additional amino acid at the N- or C-terminus of the polypeptide comprising SEQ ID NO:5.

9. (Previously Presented) The isolated polypeptide of claim 8, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4 or consists of the amino acid sequence of SEQ ID NO: 4.

10. (Currently Amended) The polypeptide of claims 1, 2 or 9, wherein the polypeptide binds to the amyloid form of the Aβ peptide comprising Aβ 1-40 peptide.

11. (Currently Amended) The polypeptide of claim[[s]] 1~~, 2 or 9~~, further comprising a therapeutic or diagnostic compound conjugated to the polypeptide.

12. (Original) A composition useful for treating or diagnosing Alzheimer's disease in a mammal comprising a pharmaceutically or diagnostically acceptable carrier and a therapeutically- or diagnostically-effective amount of a polypeptide as claimed in claims 1, 2 or 9.

13. (Withdrawn) A method of treating or diagnosing Alzheimer's disease in a mammal in need of such treatment, which comprises administering to the mammal a therapeutically- or diagnostically-effective amount of a composition as claimed in claim 12.

14. (Withdrawn) An isolated nucleic acid sequence encoding the polypeptide of claims 1, 2 or 9.

15. (Withdrawn) A vector comprising the nucleic acid sequence of claim 14.

16. (Withdrawn) The vector of claim 15, wherein the vector is an expression vector.

17. (Withdrawn) A host cell comprising the vector of claim 16.

18. (Withdrawn) The host cell of claim 17, wherein the host cell is a eukaryotic cell.

19. (Currently Amended) A hybrid molecule comprising: a) a peptide set forth in claim 1, 2 or 9, that specifically interacts with the amyloid form of the Aβ peptide comprising the Aβ 1-40 peptide; and b) a ~~scaffold molecule comprising a~~ diagnostic or therapeutic reagent.

20-23. (Cancelled)

24. (Withdrawn) A method of treating or diagnosing a neurodegenerative disease associated with aberrant plaque formation, the method comprising administering a hybrid molecule of claim 20 to a subject having, or predisposed to having, the disease.

25. (Withdrawn) The method as in claim 19, wherein said peptide binds specifically to the amyloid form of the $A\beta_{1-40}$ peptide in plaques of Alzheimer's patients.

26. (Withdrawn) An anti-idiotype antibody that specifically binds to a polypeptide of claim 1, 2 or 9.